~47 spots leftby Jun 2027

PET Scan with DPA-714 for Parkinson's Disease

Recruiting in Palo Alto (17 mi)
Jonathan E. McConathy, M.D., Ph.D ...
Overseen byJonathan McConathy, MD, PhD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Recruiting
Sponsor: University of Alabama at Birmingham
Disqualifiers: Low TSPO affinity, MRI/PET contraindication, others
No Placebo Group

Trial Summary

What is the purpose of this trial?

The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand \[18F\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The amount and distribution of \[18F\]DPA-714 in the brain will be correlated to clinical data acquired through the separate ongoing UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The primary objective of this study is to determine if patients with PD have higher levels of neuroinflammation than healthy controls as measured with \[18F\]DPA-714-PET/MRI.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team to get a clear answer.

What data supports the effectiveness of the treatment DPA-714-PET/MRI for Parkinson's Disease?

The use of PET imaging with 18F-DOPA, a similar tracer to 18F-DPA-714, has been shown to be effective in diagnosing and understanding Parkinson's Disease by highlighting brain areas affected by the disease. This suggests that DPA-714-PET/MRI might also be useful in providing valuable insights into Parkinson's Disease.12345

Is [18F]DPA-714 safe for use in humans?

The safety of [18F]DPA-714 has been studied in nonhuman primates and patients with Parkinson's disease, showing its use in imaging without reported adverse effects. However, specific safety data in humans for this compound is limited, and further studies are needed to confirm its safety profile.678910

How does the PET Scan with DPA-714 treatment for Parkinson's Disease differ from other treatments?

The PET Scan with DPA-714 is unique because it uses a specific imaging technique to visualize brain changes in Parkinson's Disease, which can help in early diagnosis and monitoring of the disease's progression. Unlike traditional treatments that focus on symptom management, this approach aims to provide a clearer understanding of the disease's impact on the brain.211121314

Research Team

Jonathan E. McConathy, M.D., Ph.D ...

Jonathan McConathy, MD, PhD

Principal Investigator

University of Alabama at Birmingham

Eligibility Criteria

This trial is for participants already enrolled in the UAB Neuroinflammation in Parkinson's Disease study. It's specifically for those who can undergo PET/MRI scans and are not pregnant or at risk of pregnancy. Individuals must have a certain genetic profile (high or mixed affinity binder) that allows them to bind well with the imaging agent used.

Inclusion Criteria

Parkinson's Disease participant enrolled in UDALL Baseline Cohort. Baseline imaging to be completed no more than 6 years prior
Enrollment in either the UAB Innate and Adaptive Immunity in Parkinson Disease (Clinical Research Core) study or UAB Longitudinal [18F]DPA-714 Imaging in a Parkinson Disease Cohort study under the separate UAB-approved research protocols (IRB-300001745 and IRB-300011684 respectively, PI Yacoubian)
I am not pregnant or have been menopausal for over a year or am surgically sterilized.
See 2 more

Exclusion Criteria

Meets any exclusion criteria for the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) study or UAB Longitudinal [18F]DPA-714 Imaging in a Parkinson's Disease Cohort study
Inability to participate in the imaging studies due to severity of PD or other medical comorbidities
Contraindication to MRI and/or PET imaging
See 1 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Imaging

Participants undergo one-time DPA-714 PET/MRI imaging to measure neuroinflammation

1 day
1 visit (in-person)

Follow-up Imaging

67 PD participants from the baseline cohort receive follow-up DPA-714 PET/MRI imaging approximately 5 years after baseline imaging

5 years
1 visit (in-person)

Metabolite Analysis

Five PD participants undergo DPA-714 PET/MRI imaging, arterial line placement, and metabolite sampling

1 day
1 visit (in-person)

Long-term Follow-up

Participants are monitored for changes in neuroinflammation and correlation with clinical data over time

2 years

Treatment Details

Interventions

  • DPA-714-PET/MRI (PET Tracer)
Trial OverviewThe substudy is testing how a PET tracer called [18F]DPA-714 distributes and concentrates in the brain, which could indicate levels of neuroinflammation in Parkinson’s patients compared to healthy individuals. The tracer binds to proteins associated with inflammation in brain immune cells.
Participant Groups
4Treatment groups
Experimental Treatment
Group I: UDALL 5-year Follow-up CohortExperimental Treatment1 Intervention
n-67 from baseline early Parkinson's disease cohort
Group II: Metabolite Analysis CohortExperimental Treatment1 Intervention
n-5 from baseline early Parkinson's disease cohort
Group III: Baseline Cohort Healthy Controls, DPA-714-PET/MRIExperimental Treatment1 Intervention
n-105
Group IV: Baseline Cohort Early Parkinson's Disease, DPA-714-PET/MRIExperimental Treatment1 Intervention
n-100

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials
1,677
Recruited
2,458,000+
Kierstin Kennedy profile image

Kierstin Kennedy

University of Alabama at Birmingham

Chief Medical Officer since 2022

MD

S. Dawn Bulgarella profile image

S. Dawn Bulgarella

University of Alabama at Birmingham

Chief Executive Officer since 2023

BSc in Commerce and Business Administration from the University of Alabama, MS in Health Administration from the University of Alabama at Birmingham

Findings from Research

Amino-acid PET imaging, particularly using 18F-DOPA, is increasingly recommended alongside MRI for evaluating and managing brain tumors, as it provides valuable insights at various stages of treatment.
There is strong evidence supporting the use of 18F-DOPA in adults for brain tumor evaluations, and emerging data suggests its effectiveness in pediatric cases as well, highlighting its potential for broader clinical applications.
Amino Acid PET Imaging with 18F-DOPA in the evaluation of Pediatric Brain Tumors.Djekidel, M., Alsadi, R., Bouhali, O., et al.[2022]
(18)F-DOPA PET imaging is the most effective diagnostic tool for identifying Parkinson's disease (PD) and other movement disorders, as it can detect presynaptic dysfunction early in the disease process.
Fluorine-18-FDG PET can help differentiate between PD and other parkinsonian syndromes, while the combination of (18)F-DOPA PET with MRI may enhance early diagnosis capabilities.
Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders.Calabria, FF., Calabria, E., Gangemi, V., et al.[2016]
Modern MRI techniques, such as iron- and neuromelanin-sensitive imaging, have revealed important markers for diagnosing Parkinson's disease (PD) and tracking its progression, which were previously overlooked.
High-field (3T) and ultra high-field (7T) MRI can capture both structural and functional brain changes, aiding in the understanding of neurodegeneration and providing potential biomarkers for therapeutic trials.
The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.Lehericy, S., Vaillancourt, DE., Seppi, K., et al.[2022]

References

Amino Acid PET Imaging with 18F-DOPA in the evaluation of Pediatric Brain Tumors. [2022]
Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders. [2016]
The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. [2022]
Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma. [2023]
A revisit to quantitative PET with 18F-FDOPA of high specific activity using a high-resolution condition in view of application to regenerative therapy. [2017]
Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging. [2021]
[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. [2022]
Whole-body biodistribution and radiation dosimetry of [18F]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders. [2023]
PET Imaging for Dynamically Monitoring Neuroinflammation in APP/PS1 Mouse Model Using [18F]DPA714. [2020]
[18F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain. [2022]
Recent advances in PET imaging for evaluation of Parkinson's disease. [2021]
Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT-a clinical comparison. [2020]
Motor disturbance and brain functional imaging in Parkinson's disease. [2018]
Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease. [2021]